TECNIS Foldable Acrylic IOL with OptiEdge, Model ZA9003
Johnson & Johnson Surgical Vision, Inc. · Decision date Oct 19, 2026
What did the FDA decide?
FDA database record P990080/S067 describes a 30-day notice for the TECNIS Foldable Acrylic IOL with OptiEdge, Model ZA9003. The stated change is the transfer of microbiology testing from an external contractor to an in-house laboratory to support product manufacturing at the AMO Puerto Rico manufacturing site. The applicant is Johnson & Johnson Surgical Vision, Inc., and the supplement type is a process change involving manufacturer, sterilizer, packager, or supplier.
This supplement does not represent a new approval of the intraocular lens system. The record identifies the original PMA number P990080, but the notice concerns only the reported testing location change. The source statement describes the purpose of the change; it does not provide independent proof of safety or clinical effectiveness. Specific details about validation results, test methods, or manufacturing impact are absent from the supplied fields.
FDA approval order statement
the transfer of microbiology testing from an external contractor to an in-house laboratory to support product manufacturing at the AMO Puerto Rico manufacturing site
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Ophthalmic
- Decision date
- Oct 19, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P990080/S067
- Regulatory pathway
- PMA supplement
- Product code
- HQL
- Decision code
- OK30
- Decision date
- Oct 19, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: intraocular lens.
- Product code
- HQL
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P990080. Subsequent supplements may change the device or its indications.
FDA decision timeline
P990080 · Original PMA
CEEON EDGE FOLDABLE ULTRAVIOLET LIGHT-ABSORBING POSTERIOR CHAMBER INTRAOCULAR LENS, MODEL 911A
P990080/S067 received
Application receipt date recorded by FDA.
P990080/S067 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P990080. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P990080
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | PMA approval | Apr 5, 2001 | FDA |
Explore the linked device profile
Other records with product code HQL
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
FINEVISION HP Trifocal IOLsP240038/S004 | Beaver-Visitec International, Inc. | PMA supplement | Oct 27, 2026 | FDA |
CT LUCIA Intraocular Lenses (IOLs)P100016/S028 | Carl Zeiss Meditec Production, LLC | PMA supplement | Oct 23, 2026 | FDA |
enVista Hydrophobic Acrylic Intraocular LensP910056/S067 | Bausch + Lomb, Inc. | PMA supplement | Oct 23, 2026 | FDA |
| Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Oct 19, 2026 | FDA | |
enVista Hydrophobic Acrylic Intraocular LensP910056/S066 | Bausch + Lomb, Inc. | PMA supplement | Oct 14, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Johnson & Johnson Surgical Vision, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 31 Technology Dr., Suite 200, Irvine, CA, 92618
Sources and methodology
- Original FDA record: P990080/S067
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



